News

Puma Biotechnology filed a new drug submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast

KN035 is an investigational programmed cell death ligand-1 (PD-L1) monoclonal antibody which has been exposed to more than 500 patients in multiple clinical trials in US, China and

Charles River said it is reaffirming the commitment to the future of drug discovery by advancing its integrated, innovative early-stage platform. As part of the deal, the partnership

US 10,166,194, entitled “Hydrocortisone Controlled Release Formulation”, is a patent claiming a method of treatment for adrenal dysfunction, including the diseases congenital adrenal hyperplasia (CAH) and adrenal insufficiency

The company submitted a supplemental new drug application (sNDA) with the regulator for new indication of Dextenza. The FDA is expected to complete the review for new indication

FLU-v is being developed by Imutex, hVIVO’s 49% joint venture with the SEEK Group. Following additional analysis of the samples from the study by the National Institute of

Under the new CLAs, Agenus will leverage Selexis’ modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins. Selexis licensing and business development vice

Sylvant secured approval in over 40 countries to treat idiopathic multicentric Castleman’s disease (iMCD), which is a subtype of Castleman disease or giant lymph node hyperplasia, lymphoid hamartoma,

Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent the diseases of aging. Its first target is